TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage
31.8.2021 09:00:00 EEST | Business Wire | Press release
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment firm Cathay Capital, led new investors and joined other institutional and individual backers while existing shareholders were led by Sofinnova Partners, a historical cornerstone investor, reinforcing TISSIUM shareholding structure. As part of the financing, Cathay Health Co-founder and Managing Partner Hongjie Hu will be joining TISSIUM’s board of directors.
This latest funding round coincides with a period of rapid growth at TISSIUM that is expected to continue as it scales its operations and adds to its executive team. The financing will allow TISSIUM to continue to execute on its development plan, funding the company up to the commercialization of its leading nerve repair, hernia repair and cardiovascular sealant products.
As TISSIUM adds to its platform with products in new therapeutic areas, it will continue to pursue rapid international expansion, leveraging in-house production and state-of-the-art manufacturing facilities, as well as entering partnerships in certain verticals.
Christophe Bancel, CEO of TISSIUM, said, “With the closing of our Series C financing round, TISSIUM is well-positioned to take the next steps to commercialization. This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. This financing will contribute significantly to TISSIUM’s ability to take advantage of the variety of opportunities we have to advance our innovation in this space.”
Antoine Papiernik, Managing Partner at Sofinnova Partners, said, “At Sofinnova Partners, we have been convinced since the beginning of TISSIUM’s potential to revolutionize tissue repair and bring a truly innovative solution for patients worldwide. We are pleased to be joined by Cathay Health and other investors who share this vision as we continue to support TISSIUM and provide the means for this exceptional team to pursue its development and prepare the commercialization of its lead products.”
Hongjie Hu, Co-founder and Managing Partner of Cathay Health, said, “TISSIUM is creating the future of tissue reconstruction on all continents. Its expandable platform is solving for widespread problems in surgeries addressing the needs of atraumatic repairs and can be applied to multiple, large, unmet therapeutic areas. As a cross-border investment platform spanning the US, Europe and Asia, we look forward to bringing the global outlook, resources and health ecosystem to support TISSIUM’s brilliant team in its international expansion and for the next steps toward commercialization and growth.”
About TISSIUM:
TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular. Each product is designed to enhance the tissue reconstruction process in a unique way. The company also develops delivery and activation devices for enhanced performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
For more information, please visit: www.TISSIUM.com
Follow us on LinkedIn, Twitter @TISSIUMtech.
About Cathay Health and Cathay Capital Group:
Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. Affiliated to Cathay Capital, Cathay Health is a global cross-border platform investing at the convergence of healthcare, life sciences and technology. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages over $4,2B in assets, has completed over 180 buyouts, growth and venture capital investments with global reach and local expertise across Paris, London, Munich, New York, Boston, San Francisco, Shanghai, Beijing, Singapore and Shenzhen.
For more information, please visit www.cathaycapital.com
Follow us on LinkedIn, Twitter @CathayCapital
About Sofinnova Partners:
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005572/en/
Contact information
Investor relations
Romain Attard – Chief Financial Officer
Tel: +33 1 76 21 72 28
rattard@tissium.com
Twitter: @TISSIUMtech
Press
Jeanene Timberlake
Tel: +1 646-770-8858
jtimberlake@rooneypartners.com
Yoann Besse
Tel: +33 6 63 03 84 91
yoann.besse@citigatedewerogerson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 18:20:00 EEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 18:00:00 EEST | Press release
Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment in cardiovascular health and its mission to care for every heartbeat. The 15-abstract showcase provides a comprehensive look at the role of bempedoic acid in lipid management. This includes post-hoc analyses in collaboration with Esperion Therapeutics from the Phase 3 CLEAR Outcomes trial exploring its impact on stroke and venous thromboembolism (VTE) incidence.5,6 There are also real-world findings from the MILOS registry, including a dedicated sub-analysis investigating the effectiveness of bempedoic acid across various background therapies.1,2,3,4 Results reinforce consistent effectiveness and safety profile of bempedoic acid across various EU countries and regardless of patients’ existing treatm
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom